- Home
- FFIC vs ATXS Comparison
FFIC vs ATXS Comparison
Compare FFIC & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFIC
- ATXS
- Stock Information
- Founded
- FFIC 1929
- ATXS 2008
- Country
- FFIC United States
- ATXS United States
- Employees
- FFIC N/A
- ATXS N/A
- Industry
- FFIC Major Banks
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- FFIC Finance
- ATXS Health Care
- Exchange
- FFIC Nasdaq
- ATXS Nasdaq
- Market Cap
- FFIC 415.1M
- ATXS 401.2M
- IPO Year
- FFIC 1995
- ATXS 2015
- Fundamental
- Price
- FFIC $11.86
- ATXS $5.26
- Analyst Decision
- FFIC Hold
- ATXS Strong Buy
- Analyst Count
- FFIC 3
- ATXS 7
- Target Price
- FFIC $16.17
- ATXS $32.43
- AVG Volume (30 Days)
- FFIC 163.2K
- ATXS 618.7K
- Earning Date
- FFIC 07-28-2025
- ATXS 05-13-2025
- Dividend Yield
- FFIC 7.32%
- ATXS N/A
- EPS Growth
- FFIC N/A
- ATXS N/A
- EPS
- FFIC N/A
- ATXS N/A
- Revenue
- FFIC $124,028,000.00
- ATXS N/A
- Revenue This Year
- FFIC $112.30
- ATXS N/A
- Revenue Next Year
- FFIC $7.61
- ATXS N/A
- P/E Ratio
- FFIC N/A
- ATXS N/A
- Revenue Growth
- FFIC N/A
- ATXS N/A
- 52 Week Low
- FFIC $10.65
- ATXS $3.56
- 52 Week High
- FFIC $18.59
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- FFIC 41.29
- ATXS 61.41
- Support Level
- FFIC $11.83
- ATXS $3.83
- Resistance Level
- FFIC $12.34
- ATXS $4.98
- Average True Range (ATR)
- FFIC 0.27
- ATXS 0.38
- MACD
- FFIC -0.07
- ATXS 0.16
- Stochastic Oscillator
- FFIC 5.08
- ATXS 87.37
About FFIC Flushing Financial Corporation
Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.